EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acquired factor VIII deficiency with rituximab



Treatment of acquired factor VIII deficiency with rituximab



Blood 96(11 Part 2): 84b, November 16



In April 1997, a 75-year-old African-American male presented with a spontaneous soft tissue hemorrhage into his neck. Tracheostomy was required to protect the airway. He was diagnosed with an acquired deficiency in factor VIII (factor VIII activity level less than 1%, factor VIII inhibitor level 150 Bethesda units). He was successfully treated with a combination of porcine factor VIII, human factor VIII and recombinant human factor VIIa (rFVIIa). He continued to suffer spontaneous hemarthrosis and soft tissue hemorrhages. Attempts to treat his underlying condition with prednisone; cyclophosphamide vincristine and prednisone; dexamethasone and cyclosporin; and intravenous immune globulin were all unsuccessful. His hemorrhages were managed with FEIBA until rFVIIa became commercially available. In March 2000, the patient was receiving rFVIIa on a daily basis for treatment of hemorrhage into his thighs. A decision was made to treat him with rituximab. The factor VIII inhibitor level of the patient was measured at 525 Bethesda units, with factor VIII activity level of less than 1% prior to institution of rituximab therapy. On April 4, 2000, the first of four weekly doses of rituximab, dosed at 375 mg/m2/week was administered without toxicity. There was a clinical response to therapy as the patient has suffered only one spontaneous hemorrhage since the administration of rituximab. There was a laboratory response to therapy as the factor inhibitor level was measured at 315 Bethesda units four weeks after completion of the rituximab therapy. Sixteen weeks after completion of the therapy, the factor VIII inhibitor level was measured at 67 Bethesda units with a factor VIII level of 7%. This case suggests that rituximab may have a role in the treatment of patients with acquired inhibitors to factor VIII.

(PDF 0-2 workdays service: $29.90)

Accession: 035980716

Download citation: RISBibTeXText



Related references

Durable responses to rituximab in acquired factor VIII deficiency. Thrombosis and Haemostasis 106(1): 172-174, 2011

Recombinant factor VIIa and factor VIII treatment for acquired factor VIII deficiency: a case of repeated thrombotic endotracheal occlusion in a mechanically ventilated patient. Critical Care 15(2): 407-407, 2013

Rituximab in the treatment of acquired factor VIII inhibitors. Thrombosis and Haemostasis 96(1): 84-87, 2006

Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 92(1): 66-71, 2007

Acquired Factor VIII Deficiency Rapid and Complete Remission after Immunosuppressive Therapy with High Dose Cyclophosphamide and Rituximab. Blood 100(11): Abstract No 3882, November 16, 2002

Successful treatment of acquired factor VIII inhibitor with rituximab in 4 patients. Blood 102(11): 798a, November 16, 2003

Successful treatment with rituximab in an elderly patient with acquired factor VIII inhibitor. Geriatrics & Gerontology International 9(2): 197-199, 2009

Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases. Transfusion Medicine 16(3): 209-212, 2006

Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia 13(1): 46-50, 2007

The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group. Seminars in Hematology 30(2 Suppl 1): 22-27, 1993

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 101(9): 3753-4; Author Reply 3754-5, 2003

Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature. Clinical and Applied Thrombosis/Hemostasis 13(4): 443-448, 2007

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 14(5): 898-902, 2008

Suppression of autoantibodies to factor VIII and correction of factor VIII deficiency with a combined steroid-cyclophosphamide-porcine factor VIII treatment in a patient with rheumatoid arthritis. Journal of Internal Medicine 231(6): 617-619, 1992

Successful treatment of acquired factor VIII deficiency in a child using activated factor VII concentrates: case report and review of the literature. Journal of Pediatric Hematology/Oncology 25(7): 578-580, 2003